GLP-1 drugs like Ozempic have become famous for weight loss and blood-sugar control — and increasingly for protecting the heart. A large new study delivers a pointed warning: stopping them may undo much of that heart protection, and surprisingly quickly.
What the study found
Researchers at Washington University School of Medicine in St. Louis analyzed records from 333,687 U.S. veterans with type 2 diabetes — 132,551 on GLP-1 drugs and 201,136 on an older class (sulfonylureas) for comparison — over three years. The key finding: patients who stopped GLP-1 therapy saw their cardiovascular risk climb the longer they were off it. After one year off, they had a 14% higher risk of heart attack, stroke and death compared with continuous users; after two years, the gap widened to 22%. Even a six-month interruption showed a meaningful increase. The work was published in BMJ Medicine.
Why stopping hurts
The likely reason is that these drugs treat chronic, underlying conditions that come roaring back when treatment ends. “When they stop, it’s not just weight that comes back; they experience a resurgence in inflammation, blood pressure, and cholesterol,” explained senior researcher Ziyad Al-Aly. In other words, the cardiovascular benefit isn’t a one-time reset — it’s maintained only as long as the drug is keeping those risk factors in check.
The most striking detail
Perhaps the study’s most sobering finding: restarting the medication restored only partial protection, suggesting that a period off the drug “leaves a lasting scar.” If confirmed, that implies the damage from interruptions isn’t fully reversible — a strong argument for staying on treatment consistently rather than cycling on and off.
What it means for how these drugs are used
The implication is that GLP-1 medicines behave like chronic therapies — akin to blood-pressure or cholesterol drugs — where benefits accumulate slowly but vanish rapidly upon stopping, requiring indefinite adherence to maintain heart protection. That matters enormously in the real world, where many people stop these drugs because of cost, side effects, shortages or the assumption that they can quit once they’ve lost weight.
The caveats
This is an observational study, so it shows association, not proof of cause: people who stop their medication may differ in ways that also raise cardiovascular risk. The population was mostly older male veterans with diabetes, which may limit how broadly the findings apply. And nothing here says people should never stop — sometimes stopping is medically necessary. The takeaway is not to quit abruptly on your own: if you’re considering stopping a GLP-1 drug, discuss it with your doctor, who can weigh the risks. This summarizes research and is not medical advice.